Acadian Asset Management LLC boosted its holdings in shares of Minerva Neurosciences, Inc. (NASDAQ:NERV) by 86.6% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,705,195 shares of the biopharmaceutical company’s stock after buying an additional 791,485 shares during the period. Acadian Asset Management LLC’s holdings in Minerva Neurosciences were worth $5,423,000 as of its most recent SEC filing.
A number of other large investors have also bought and sold shares of the stock. Wells Fargo & Company MN boosted its stake in Minerva Neurosciences by 37.4% during the first quarter. Wells Fargo & Company MN now owns 18,766 shares of the biopharmaceutical company’s stock valued at $113,000 after buying an additional 5,112 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in shares of Minerva Neurosciences by 7.7% in the second quarter. Charles Schwab Investment Management Inc. now owns 78,749 shares of the biopharmaceutical company’s stock worth $285,000 after buying an additional 5,620 shares during the period. BNP Paribas Arbitrage SA increased its holdings in shares of Minerva Neurosciences by 226.8% in the third quarter. BNP Paribas Arbitrage SA now owns 8,148 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 5,655 shares during the period. Raymond James Financial Services Advisors Inc. increased its holdings in Minerva Neurosciences by 40.4% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 35,100 shares of the biopharmaceutical company’s stock valued at $127,000 after purchasing an additional 10,100 shares during the period. Finally, Virtu Financial LLC purchased a new position in Minerva Neurosciences during the 2nd quarter valued at about $39,000. 67.42% of the stock is owned by institutional investors.
Minerva Neurosciences stock opened at $3.68 on Friday. Minerva Neurosciences, Inc. has a 1-year low of $1.81 and a 1-year high of $15.22. The firm has a market capitalization of $157.04 million, a P/E ratio of -6.81 and a beta of 1.50. The company’s 50-day moving average is $3.37 and its 200 day moving average is $4.56.
A number of brokerages have recently commented on NERV. William Blair reissued a “hold” rating on shares of Minerva Neurosciences in a research report on Friday, September 11th. Zacks Investment Research lowered shares of Minerva Neurosciences from a “buy” rating to a “hold” rating in a report on Tuesday, October 6th. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $6.20.
About Minerva Neurosciences
Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of schizophrenia.
Featured Article: What is a Buy-Side Analyst?
Want to see what other hedge funds are holding NERV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Minerva Neurosciences, Inc. (NASDAQ:NERV).
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.